article Open AccessTop 1% cited

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

New England Journal of Medicine · 2011 · Vol. 364(26) · pp. 2507–2516

Paul B. Chapman✉(Memorial Sloan Kettering Cancer Center)Axel Hauschild(Kiel University)Caroline Robert(Institut Gustave Roussy)John B.A.G. Haanen(The Netherlands Cancer Institute)Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")James Larkin(Royal Marsden Hospital)Reinhard Dummer(University of Zurich)Claus Garbe(University of Tübingen)Alessandro Testori(European Institute of Oncology)Michele Maio(Tumour Institute of Tuscany)David Hogg(University Health Network)Paul Lorigan(University of Manchester)Célèste Lebbé(Hôpital Saint-Louis)Thomas Jouary(Hôpital Saint-André)Dirk Schadendorf(Essen University Hospital)Antoni Ribas(University of California, Los Angeles)Steven O’Day(Angeles Clinic and Research Institute)Jeffrey A. Sosman(Vanderbilt University)John M. Kirkwood(University of Pittsburgh)Alexander M.M. Eggermont(Institut Gustave Roussy)Brigitte Dréno(Nantes Université)K. B. NolopJiang Li(La Roche College)B. NelsonJeannie HouRichard J. Lee(La Roche College)Keith T. Flaherty(Massachusetts General Hospital)Grant A. McArthur(Peter MacCallum Cancer Centre)

View via DOI Full-text PDF

Abstract

Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).

Melanoma and MAPK Pathways Cutaneous Melanoma Detection and Management Colorectal Cancer Treatments and StudiesVemurafenibMedicineDacarbazineInterim analysisInternal medicineAdverse effectMelanomaOncologyRashDabrafenib